Drugs / THK5351
THK5351
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04318626 | Nov 2020 → Jul 2023 | cognitive disorder | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04588649 | Jan → Mar 2016 | cerebrovascular disorder, dementia | Chang Gung Memorial Hospital | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THK-5351 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04588649 ↗ |
| Known as | (S)-6-\[(3-Fluoro-2-hydroxy)propoxy\]-2-(2-Methylaminopyrid-5-yl)-quinoline | “Name: \[18F\]THK5351，(S)-6-\[(3-Fluoro-2-hydroxy)propoxy\]-2-(2-Methylaminopyrid-5-yl)-quinoline Dosage form: intravenous injection” NCT04588649 ↗ |
| Known as | \[18F\]THK-5351 | “\[18F\]THK-5351 PET Imaging” NCT04588649 ↗ |
| Known as | J3.349.111E | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650352 ↗ |
| Modality | Small molecule | — CHEMBL4650352 ↗ |
| Route | Intravenous | “Dosage form: intravenous injection” NCT04318626 ↗ |